Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
Sponsor: Emmecell
Summary
This study will evaluate the safety and effectiveness of a single injection of EO2002 at one of two dose levels (150,000 or 500,000 magnetic human corneal endothelial cells \[mHCECs\]), compared with a placebo injection, in participants with corneal edema caused by corneal endothelial dysfunction.
Official title: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 2 Study of EO2002 in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction (EMERALD)
Key Details
Gender
All
Age Range
21 Years - Any
Study Type
INTERVENTIONAL
Enrollment
121
Start Date
2026-09
Completion Date
2028-02
Last Updated
2026-07-29
Healthy Volunteers
No
Conditions
Interventions
150K cells
Intracameral injection - 150K dose
500K cells
Intracameral injection - 500K dose
Placebo
Intracameral injection of vehicle
Locations (1)
Clinical Site 1
Menlo Park, California, United States